GC Wealth Management RIA LLC Cuts Stock Holdings in Pfizer Inc. $PFE

Key Points

• GC Wealth Management RIA LLC trimmed its Pfizer stake by 72.6% in Q4, selling 48,783 shares and leaving 18,456 shares valued at about $460,000.
• Pfizer has several near‑ and medium‑term positive catalysts — including an FDA approval for a Pfizer–Arvinas breast cancer therapy, settlements extending Vyndamax exclusivity to 2031, a late‑stage win for Elrexfio, and a PADCEV sBLA accepted for priority review — which bolster revenue visibility despite some analyst caution.
• Financially, Pfizer beat Q4 EPS estimates and has a market cap near $150 billion; it also announced a quarterly dividend yielding 6.5% (ex‑dividend date May 8), while analysts’ consensus rating remains a “Hold” with an average price target of $28.74.

GC Wealth Management RIA LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 72.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,456 shares of the biopharmaceutical company's stock after selling 48,783 shares during the period. GC Wealth Management RIA LLC's holdings in Pfizer were worth $460,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PFE. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 645 shares during the period. YANKCOM Partnership purchased a new stake in shares of Pfizer during the fourth quarter worth about $28,000. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer during the third quarter worth about $29,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the second quarter worth about $32,000. Finally, True Wealth Design LLC boosted its holdings in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 974 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval for a Pfizer–Arvinas breast cancer therapy — The U.S. FDA approved the co‑developed drug for a breast cancer indication, giving Pfizer an additional commercial launch and validating its oncology partnership pipeline. This approval creates a new near‑ and medium‑term revenue opportunity and reduces development risk for the asset. US FDA approves Pfizer, Arvinas' breast cancer drug
• Positive Sentiment: Vyndamax patent settlements extend exclusivity to 2031 — Pfizer reached settlements with multiple generic filers that effectively push back generic entry for Vyndamax (tafamidis), protecting a meaningful revenue stream and reducing downside risk from near‑term generic competition. That supports cash flow visibility into the next decade. Pfizer Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
• Positive Sentiment: Late‑stage win for multiple myeloma drug Elrexfio — Pfizer reported a late‑stage trial success for Elrexfio, which could expand its oncology franchise and add future revenue streams if regulatory filings follow. Clinical wins can meaningfully re‑rate biotech exposure over time. Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
• Positive Sentiment: PADCEV supplemental BLA accepted for priority review — Pfizer (with Astellas) secured FDA acceptance of a PADCEV sBLA for a new use, which could expand indications and sales if approved. This is another program that supports medium‑term growth optionality. Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings and guidance in focus (May 5) — Wall Street is watching first‑quarter results and guidance; Zacks and other outlets highlight consensus estimates and key revenue/margin line items, with traders positioning ahead of potential beats and for commentary on obesity and specialty drug performance. Earnings will likely be the short‑term catalyst for direction. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Negative Sentiment: Analyst caution and price‑target cuts are weighing on sentiment — Goldman reportedly trimmed its target and some sell‑side commentary highlights growth concerns despite the patent wins; Morgan Stanley reiterated Equal Weight and flagged patent/growth uncertainty. That cautious analyst tone can sap momentum and contribute to intraday selling. Pfizer Stock Opinions on Vyndamax Settlements and Earnings Outlook Morgan Stanley Maintains Pfizer at Equal Weight

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Cantor Fitzgerald reiterated a "neutral" rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price for the company in a report on Monday, March 2nd. UBS Group increased their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Monday, April 13th. Morgan Stanley increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an "equal weight" rating in a report on Friday, April 10th. Finally, CICC Research began coverage on shares of Pfizer in a report on Thursday, April 16th. They set an "outperform" rating and a $33.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of "Hold" and an average price target of $28.74.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.35 on Friday. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The company has a 50 day simple moving average of $27.17 and a two-hundred day simple moving average of $26.09. The company has a market capitalization of $149.80 billion, a price-to-earnings ratio of 19.37 and a beta of 0.35. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the firm earned $0.63 earnings per share. The business's revenue for the quarter was down 1.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer's dividend payout ratio (DPR) is currently 126.47%.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.